Page last updated: 2024-10-25

citalopram and Arrhythmia

citalopram has been researched along with Arrhythmia in 22 studies

Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.

Research Excerpts

ExcerptRelevanceReference
"The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease."9.19Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014)
"This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks."9.12Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007)
"The selective serotonin reuptake inhibitors (SSRIs) citalopram and escitalopram are associated with QT prolongation, which increases the risk of serious arrhythmia."8.12Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults. ( Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK, 2022)
"The effect of citalopram (CTP) a selective serotonin reuptake inhibitor agent was studied on ouabain-induced arrhythmia in spontaneously beating isolated guinea-pig atria."7.72Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria. ( Malihi, G; Naghibi, B; Pousti, A, 2003)
"The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease."5.19Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. ( Devanand, DP; Drye, LT; Frangakis, C; Ismail, Z; Lyketsos, CG; Marano, C; Meinert, CL; Mintzer, JE; Munro, CA; Pelton, G; Pollock, BG; Porsteinsson, AP; Rabins, PV; Rosenberg, PB; Schneider, LS; Shade, DM; Weintraub, D; Yesavage, J, 2014)
"This was a randomized, double-blind, placebo- and active comparator-controlled study, in which patients (> or = 18 years) meeting DSM-IV criteria for Major Depressive Disorder (MDD) received duloxetine 60 mg once daily (QD; N = 273), escitalopram 10 mg QD (N = 274), or placebo (N = 137) for 8 weeks."5.12Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. ( Greist, JH; Mallinckrodt, CH; Nierenberg, AA; Prakash, A; Sambunaris, A; Tollefson, GD; Wohlreich, MM, 2007)
"The selective serotonin reuptake inhibitors (SSRIs) citalopram and escitalopram are associated with QT prolongation, which increases the risk of serious arrhythmia."4.12Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults. ( Aakjaer, M; Andersen, M; De Bruin, ML; Werther, SK, 2022)
"This study compares the risks of arrhythmia among patients with depression receiving selective serotonin reuptake inhibitors (SSRIs) and those receiving other classes of antidepressants and among patients with depression receiving citalopram-escitalopram and those receiving other SSRIs."3.91Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study. ( Hansen, RA; Lin, YT; Lu, TS; Wang, CC, 2019)
"Citalopram daily doses >40 mg were associated with lower risks of ventricular arrhythmia (adjusted hazard ratio=0."3.79Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg. ( Blow, FC; Bohnert, AS; Ganoczy, D; Kales, HC; Nallamothu, BK; Pfeiffer, PN; Zivin, K, 2013)
" In the first case, the drugs venlafaxine, amiodarone and domperidone may have contributed to QT interval prolongation in a patient with hypokalemia and hypomagnesaemia."3.76Multifactorial QT interval prolongation. ( Baranchuk, A; Digby, G; Machaalany, J; Malik, P; Methot, M; Redfearn, D; Simpson, CS, 2010)
" A 52-year-old man with a history of depression treated with escitalopram 10 mg/day, extended-release morphine 30 mg/day and zopiclone 15 mg/day was found unconscious at his home."3.74Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines. ( Baranchuk, A; Gibson, K; Methot, M; Simpson, CS; Strum, D, 2008)
"The effect of citalopram (CTP) a selective serotonin reuptake inhibitor agent was studied on ouabain-induced arrhythmia in spontaneously beating isolated guinea-pig atria."3.72Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria. ( Malihi, G; Naghibi, B; Pousti, A, 2003)
"The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation."1.51Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. ( Beaussier, H; Bézie, Y; Chastang, A; Corny, J; Lillo-Lelouet, A; Petre, A; Phan Thi, TT; Renet, S, 2019)
"Although the US Food and Drug Administration (FDA) recommended upper limits for citalopram dosing in older adults due to risk of corrected-QT (QTc) prolongation, which was adopted, and extended to escitalopram by Health Canada, the scientific basis is unclear."1.51Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. ( Brown, HK; Crépeau-Gendron, G; Koh, S; Madan, R; Mah, L; Shorey, C; Szabuniewicz, C; Veinish, S, 2019)
"Escitalopram has a small effect on the QTc interval."1.38A question about the potential cardiac toxicity of escitalopram. ( Howland, RH, 2012)
"There were no deaths, seizures, or arrhythmias."1.35Clinical and ECG effects of escitalopram overdose. ( Isbister, GK; van Gorp, F; Whyte, IM, 2009)

Research

Studies (22)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (27.27)29.6817
2010's14 (63.64)24.3611
2020's2 (9.09)2.80

Authors

AuthorsStudies
Jia, L1
Sun, H1
Aakjaer, M1
Werther, SK1
De Bruin, ML1
Andersen, M1
Czaja, AS1
Anderson, HD1
Ghosh, D1
Davidson, J1
Campbell, JD1
Valuck, RJ1
Ojero-Senard, A1
Benevent, J1
Bondon-Guitton, E1
Durrieu, G1
Chebane, L1
Araujo, M1
Montastruc, F1
Montastruc, JL1
Farkas, AN1
Marcott, M1
Yanta, JH1
Pizon, AF1
Chastang, A1
Renet, S1
Corny, J1
Beaussier, H1
Petre, A1
Lillo-Lelouet, A1
Phan Thi, TT1
Bézie, Y1
Crépeau-Gendron, G1
Brown, HK1
Shorey, C1
Madan, R1
Szabuniewicz, C1
Koh, S1
Veinish, S1
Mah, L1
Lin, YT1
Lu, TS1
Hansen, RA1
Wang, CC1
Zivin, K1
Pfeiffer, PN1
Bohnert, AS1
Ganoczy, D1
Blow, FC1
Nallamothu, BK1
Kales, HC1
Wang, SM1
Pae, CU1
Porsteinsson, AP1
Drye, LT1
Pollock, BG1
Devanand, DP1
Frangakis, C1
Ismail, Z1
Marano, C1
Meinert, CL1
Mintzer, JE1
Munro, CA1
Pelton, G1
Rabins, PV1
Rosenberg, PB1
Schneider, LS1
Shade, DM1
Weintraub, D1
Yesavage, J1
Lyketsos, CG1
Kumar, Y1
Kung, S1
Shinozaki, G1
Zhang, Y1
Baranchuk, A3
Hancox, JC1
Gioia, S1
Lancia, M1
Bacci, M1
Suadoni, F1
Simpson, CS2
Methot, M2
Gibson, K1
Strum, D1
van Gorp, F1
Whyte, IM1
Isbister, GK1
Digby, G1
Machaalany, J1
Malik, P1
Redfearn, D1
Howland, RH2
Pousti, A1
Malihi, G1
Naghibi, B1
Vinter, S1
Isaksen, C1
Vesterby, A1
Nierenberg, AA1
Greist, JH1
Mallinckrodt, CH1
Prakash, A1
Sambunaris, A1
Tollefson, GD1
Wohlreich, MM1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-Center Randomized Placebo-Controlled Clinical Trial Study of Citalopram for the Treatment of Agitation in Alzheimer's Disease[NCT00898807]Phase 3186 participants (Actual)Interventional2009-07-31Completed
Duloxetine Versus Escitalopram and Placebo in the Treatment of Patients With Major Depression[NCT00073411]Phase 3675 participants Interventional2003-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Cohen-Mansfield Agitation Inventory (CMAI)

CMAI examines several agitated behaviors including verbal, physical agitation, and other behaviors. Sub-items are summed. Range is 14-70. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention27.7
Placebo and Psychosocial Intervention28.7

Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in Agitation(CGIC)

"Modified Alzheimer's Disease Cooperative Study- Clinical Global Impression of Change in agitation(CGIC) accesses clinically significant change in agitation. A trained clinician, blind to treatment assignment, uses a 7-point Likert scale to rate change of each patient along a continuum from marked improvement(1), no change(4), and marked worsening(7). A number of aspects of the agitation is considered such as emotional agitation, mood liability/distress, psychomotor agitation, verbal aggression, and physical aggression. Range is 1-7." (NCT00898807)
Timeframe: Baseline to 9 weeks

Interventionpercentage moderate/marked improvement (Number)
Citalopram and Psychosocial Intervention40
Placebo and Psychosocial Intervention26

NeuroBehavior Rating Scale-- Agitation

NeuroBehavioral Rating Scale- Agitation(NBRS-A) assesses multiple types of psychopathology common in dementia and is based on a seven point Likert scale of increasing severity for each item(i.e., 0=not present, 1=very mild, 2-mild, 3=moderate, 4=moderately severe, 5=severe, 6=extremely severe). The NBRS agitation subscore includes NBRS 'inhibition', 'agitation', and 'hostility'. The range is 0 to 18 points. Higher scores indicate more symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention4.33
Placebo and Psychosocial Intervention5.26

Neuropsychiatric Inventory (NPI)-- Agitation Subscore

NPI agitation score is based on responses from an informed caregiver involved in the patient's life. Symptom severity (1=mild, 2=moderate, 3=severe) is multiplied by frequency (1=occasionally, less than once/week; 4 = very frequently, once or more/day or continuously) to obtain the NPI agitation score.Range is 0-12. Higher scores indicate more severe symptoms. (NCT00898807)
Timeframe: 9 weeks

Interventionunits on a scale (Mean)
Citalopram and Psychosocial Intervention7.8
Placebo and Psychosocial Intervention8.0

Reviews

2 reviews available for citalopram and Arrhythmia

ArticleYear
How much to worry about the FDA warning in the use of citalopram?
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:8

    Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Citalopram; Humans; United States; U

2013
Towards limiting QT interval prolongation and arrhythmia risk in citalopram use.
    Cardiology journal, 2014, Volume: 21, Issue:5

    Topics: Arrhythmias, Cardiac; Citalopram; Depression; Electrocardiography; Global Health; Humans; Incidence;

2014

Trials

2 trials available for citalopram and Arrhythmia

ArticleYear
Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial.
    JAMA, 2014, Feb-19, Volume: 311, Issue:7

    Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Caregi

2014
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
    Current medical research and opinion, 2007, Volume: 23, Issue:2

    Topics: Adult; Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Double-Blind Me

2007

Other Studies

18 other studies available for citalopram and Arrhythmia

ArticleYear
Support vector machines classification of hERG liabilities based on atom types.
    Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11

    Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant

2008
Serious arrhythmia in initiators of citalopram, escitalopram, and other selective serotonin reuptake inhibitors: A population-based cohort study in older adults.
    Clinical and translational science, 2022, Volume: 15, Issue:9

    Topics: Aged; Arrhythmias, Cardiac; Citalopram; Cohort Studies; Escitalopram; Humans; Selective Serotonin Re

2022
Increased Odds of Ventricular Arrhythmias Associated with Selective Serotonin Reuptake Inhibitor Use among the Pediatric and Young Adult Population: A Case-Control Study.
    The Journal of pediatrics, 2020, Volume: 226

    Topics: Adolescent; Age Factors; Arrhythmias, Cardiac; Case-Control Studies; Child; Child, Preschool; Citalo

2020
A comparative study of QT prolongation with serotonin reuptake inhibitors.
    Psychopharmacology, 2017, Volume: 234, Issue:20

    Topics: Adult; Aged; Arrhythmias, Cardiac; Citalopram; Databases, Factual; Female; Fluvoxamine; Humans; Long

2017
Bicarbonate refractory QRS prolongation and left bundle-branch block following escitalopram and lamotrigine overdose: A case report and literature review of toxic left bundle-branch block.
    Journal of clinical pharmacy and therapeutics, 2018, Volume: 43, Issue:5

    Topics: Adult; Arrhythmias, Cardiac; Bicarbonates; Bundle-Branch Block; Citalopram; Electrocardiography; Fem

2018
Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
    International journal of clinical pharmacy, 2019, Volume: 41, Issue:1

    Topics: Adult; Aged; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Citalopram; Drug In

2019
Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
    Journal of affective disorders, 2019, 05-01, Volume: 250

    Topics: Aged; Arrhythmias, Cardiac; Citalopram; Electrocardiography; Electronic Health Records; Female; Heal

2019
Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
    Clinical therapeutics, 2019, Volume: 41, Issue:6

    Topics: Antidepressive Agents; Arrhythmias, Cardiac; Citalopram; Depression; Humans; Retrospective Studies;

2019
Evaluation of the FDA warning against prescribing citalopram at doses exceeding 40 mg.
    The American journal of psychiatry, 2013, Volume: 170, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Citalopram; Depressive Disorder; Female; Heart

2013
CYP2C19 variation, not citalopram dose nor serum level, is associated with QTc prolongation.
    Journal of psychopharmacology (Oxford, England), 2014, Volume: 28, Issue:12

    Topics: Adult; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Citalopram; Cytoch

2014
A Fatal Case of Acute Butane-Propane Poisoning in a Prisoner Under Psychiatric Treatment: Do These 2 Factors Have an Arrhythmogenic Interaction, Thus Increasing the Cardiovascular Risk Profile?
    The American journal of forensic medicine and pathology, 2015, Volume: 36, Issue:4

    Topics: Adult; Antipsychotic Agents; Arrhythmias, Cardiac; Butanes; Chlorpromazine; Citalopram; Drug Interac

2015
Corrected QT interval prolongation after an overdose of escitalopram, morphine, oxycodone, zopiclone and benzodiazepines.
    The Canadian journal of cardiology, 2008, Volume: 24, Issue:7

    Topics: Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Azabicyclo Compounds; Benzodiazepine

2008
Clinical and ECG effects of escitalopram overdose.
    Annals of emergency medicine, 2009, Volume: 54, Issue:3

    Topics: Adolescent; Adult; Arrhythmias, Cardiac; Citalopram; Dose-Response Relationship, Drug; Drug Interact

2009
Multifactorial QT interval prolongation.
    Cardiology journal, 2010, Volume: 17, Issue:2

    Topics: Alcoholism; Amiodarone; Antipsychotic Agents; Arrhythmias, Cardiac; Biomarkers; Citalopram; Cyclohex

2010
A critical evaluation of the cardiac toxicity of citalopram: part 2.
    Journal of psychosocial nursing and mental health services, 2011, Volume: 49, Issue:12

    Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Citalopram; Cytochrome P-450 Enzyme System; Dose-Resp

2011
A question about the potential cardiac toxicity of escitalopram.
    Journal of psychosocial nursing and mental health services, 2012, Volume: 50, Issue:4

    Topics: Arrhythmias, Cardiac; Citalopram; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibitors;

2012
Effect of citalopram on ouabain-induced arrhythmia in isolated guinea-pig atria.
    Human psychopharmacology, 2003, Volume: 18, Issue:2

    Topics: Animals; Arrhythmias, Cardiac; Citalopram; Dose-Response Relationship, Drug; Drug Interactions; Fema

2003
Sudden cardiac death in a young woman: tumor of the atrioventricular (AV) node or citalopram intoxication?
    The American journal of forensic medicine and pathology, 2005, Volume: 26, Issue:4

    Topics: Adult; Antibodies, Neoplasm; Antidepressive Agents, Second-Generation; Arrhythmias, Cardiac; Atriove

2005